SCHEMBL5536264

SCHEMBL5536264

FC(F)(F)Oc1ccc(NC2CCNCC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.64
CTSL P07711 2/20 0.59
CTSB P07858 2/20 0.59
CTSS P25774 2/20 0.59
CTSK P43235 2/20 0.59
EPHX2 P34913 7/20 0.46
HTR2C P28335 1/20 0.44
MAPT P10636 1/20 0.44
GALR2 O43603 1/20 0.43
GALR1 P47211 1/20 0.43
PIM1 P11309 1/20 0.43
PIM3 Q86V86 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
MAPK1 P28482 1/20 0.41
SYK P43405 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
ABL1 P00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL411544 0.98 EPHX1 (0.63) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL2172826 0.88 EPHX2 (0.51) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL14916657 0.85 EPHX2 (0.56) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL14997954 0.84 EPHX1 (0.61) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL2093841 0.81 GALR2 (0.46) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL12953404 0.81 EPHX2 (0.56) EPHX1CTSLCTSBCTSSCTSK
Hydrochloric Acid SCHEMBL31155662 0.80 EPHX1 (0.47) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL12953129 0.79 EPHX2 (0.58) EPHX1EPHX2MAPTGALR2GALR1
SCHEMBL2718899 0.79 EPHX1 (1.00) EPHX1EPHX2
SCHEMBL1704613 0.78 HTR6 (0.57) HTR2CMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661964-A1 COMPOUNDS AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-12-17 EP disclosed
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 US disclosed
WO-2024165453-A1 COMPOUNDS AS CCR6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-08-15 WO disclosed
US-10010538-B2 Use of anthelmintic agents against Dirofilaria immitis INTERVET INC. (US) 2018-07-03 US disclosed
US-10010538-B2 Use of anthelmintic agents against Dirofilaria immitis INTERVET INC. (US) 2018-07-03 US disclosed
US-20170334927-A1 Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) 2017-11-23 US disclosed
US-20170334927-A1 Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) 2017-11-23 US disclosed
US-20170202816-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-20 US disclosed
US-20170202816-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-20 US disclosed
CN-102234287-B Nitro glyoxaline compound, Preparation Method And The Use SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) 2015-08-05 CN disclosed
CN-102234287-A Nitro imidazole compound, its preparation method and application SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD 2011-11-09 CN disclosed
WO-2011134296-A1 (6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B] [1,3]OXAZIN-6-YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF 上海阳帆医药科技有限公司 (CN) 2011-11-03 WO disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334927-A1 Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing NISCH, CYP51A1, CYP4F11 EPHX1 3791/4885CTSL 2130/4885CTSB 3989/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX1 4071/4885CTSL 4249/4885CTSB 4095/4885
US-10010538-B2 Use of anthelmintic agents against Dirofilaria immitis MPO, DHODH, DHX35 EPHX1 135/4885CTSL 441/4885CTSB 236/4885
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS CCR6, CCR4, CCR1 EPHX1 703/4885CTSL 2438/4885CTSB 2561/4885
US-20170202816-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS MPO, DHODH, DHX35 EPHX1 135/4885CTSL 441/4885CTSB 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.